| Literature DB >> 26891051 |
Anne Hecksteden1, Sabrina Skorski1, Sascha Schwindling1, Daniel Hammes1, Mark Pfeiffer2, Michael Kellmann3,4, Alexander Ferrauti3, Tim Meyer1.
Abstract
Assessing current fatigue of athletes to fine-tune training prescriptions is a critical task in competitive sports. Blood-borne surrogate markers are widely used despite the scarcity of validation trials with representative subjects and interventions. Moreover, differences between training modes and disciplines (e.g. due to differences in eccentric force production or calorie turnover) have rarely been studied within a consistent design. Therefore, we investigated blood-borne fatigue markers during and after discipline-specific simulated training camps. A comprehensive panel of blood-born indicators was measured in 73 competitive athletes (28 cyclists, 22 team sports, 23 strength) at 3 time-points: after a run-in resting phase (d 1), after a 6-day induction of fatigue (d 8) and following a subsequent 2-day recovery period (d 11). Venous blood samples were collected between 8 and 10 a.m. Courses of blood-borne indicators are considered as fatigue dependent if a significant deviation from baseline is present at day 8 (Δfatigue) which significantly regresses towards baseline until day 11 (Δrecovery). With cycling, a fatigue dependent course was observed for creatine kinase (CK; Δfatigue 54±84 U/l; Δrecovery -60±83 U/l), urea (Δfatigue 11±9 mg/dl; Δrecovery -10±10 mg/dl), free testosterone (Δfatigue -1.3±2.1 pg/ml; Δrecovery 0.8±1.5 pg/ml) and insulin linke growth factor 1 (IGF-1; Δfatigue -56±28 ng/ml; Δrecovery 53±29 ng/ml). For urea and IGF-1 95% confidence intervals for days 1 and 11 did not overlap with day 8. With strength and high-intensity interval training, respectively, fatigue-dependent courses and separated 95% confidence intervals were present for CK (strength: Δfatigue 582±649 U/l; Δrecovery -618±419 U/l; HIIT: Δfatigue 863±952 U/l; Δrecovery -741±842 U/l) only. These results indicate that, within a comprehensive panel of blood-borne markers, changes in fatigue are most accurately reflected by urea and IGF-1 for cycling and by CK for strength training and team sport players.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26891051 PMCID: PMC4758695 DOI: 10.1371/journal.pone.0148810
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Design.
Assessment of discipline specific performance (overview).
| Cycling | HIIT | Strength | |
|---|---|---|---|
| Test | Cycling time trial (♂ 40km¸♀ 20km)—Own bike fixed on ergometer | Repeated sprint test on a non-motorized treadmill (6x4 s; 20 s rest) | Half squat and bench press |
| Criterion parameter | Overall performance time [s] | Mean peak velocity [m*s-1] | Maximal voluntary isometric contraction force (MVIC; [N]) Mean of the two exercises |
Please compare supplemental material (S1 Text) for reproducible details.
Fig 2Schedules of discipline specific simulated training camps.
Subject characteristics.
| Cycling | HIIT | Strength | p | |
|---|---|---|---|---|
| n | 28 (♂: 23; ♀: 5) | 22 (♂: 11; ♀: 11) | 23 (♂: 14; ♀:9) | 0.05 |
| Age (years) | 29±7 | 23±3 | 24±2 | |
| Height (cm) | 178±7 | 177±8 | 175±8 | 0.22 |
| Weight (kg) | 72±9 | 70±7 | 72±11 | 0.67 |
| VO2peak (ml/kg/min) | 58±8 | 58±10 | 53±8 | |
| Max. workload | 338±30 (W) | 16.3±2.1 (km/h) | 15.7±1.7 (km/h) |
Means ± standard deviation; VO2peak: Peak oxygen uptake
*: Stepwise incremental cycling test
#: Stepwise incremental treadmill test
§: for sex ratio
Fig 3Courses of selected blood-born parameters.
Means ± 95% confidence intervals (for CRP: median and interquartile range). Blue: cyclists; red: ballgame players; green: strength athletes.
Changes in blood-born indicators of fatigue and recovery.
| Endurance | HIIT | Strength | ||||
|---|---|---|---|---|---|---|
| Fatigue | Recovery | Fatigue | Recovery | Fatigue | Recovery | |
| ΔCK [U/l] | ||||||
| p | ||||||
| Δ Urea [mg/dl] | 2 ± 6 | -2 ± 7 | 1 ± 9 | 2 ± 8 | ||
| p | n.a. | n.a. | n.a. | n.a. | ||
| Δ CRP [ng/ml]p | ||||||
| Δ f-T [pg/ml] | -1.5 ± 2.0 | 0.1 ± 2.0 | -1.3 ± 4.2 | 0.0 ± 1.5 | ||
| p | 0.027 | 0.964 | n.a. | n.a. | ||
| Δ Cortisol [μg/dl] | -0.9 ± 3.7 | 0.7 ± 4.2 | 1.3 ± 4.3 | 0.9 ± 5.1 | -0.6 ± 4.9 | -0.4 ± 4.7 |
| p | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| Δ fT/Cortisol [] *108 | -0.1 ± 0.2 | -0.1 ± 0.4 | 0.1 ± 0.5 | 0.0 ± 0.5 | ||
| p | 0.197 | 0.317 | n.a. | n.a. | ||
| Δ Gln [μmol/l] | -1 ± 77 | 12 ± 64 | 50 ± 75 | 19 ± 83 | 80 ± 128 | -53 ± 111 |
| p | n.a. | n.a. | <0.05 | 0.979 | 0.008 | 0.105 |
| Δ Glu [μmol/l] | 4 ± 9 | 5 ± 11 | -6 ± 9 | 6 ± 9 | 9 ± 14 | 10 ± 16 |
| p | 0.181 | 0.043 | n.a. | n.a. | 0.013 | 0.013 |
| Δ Gln/Glu [] | -4 ± 9 | -2 ± 8 | 3 ± 4 | -2 ± 4 | -5 ± 9 | -3 ± 4 |
| p | 0.081 | 0.575 | 0.021 | 0.082 | 0.030 | 0.223 |
| Δ IL 6 [pg/ml] | 0.4 ± 4.2 | -0.2 ± 4.1 | -0.3 ± 1.9 | 0.3 ± 0.8 | 0.7 ± 2.0 | -0.2 ± 2.4 |
| p | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| Δ HGH [ng/ml] | -0.9 ± 3.6 | 0.0 ± 6.3 | 0.4 ± 4.6 | -1.2 ± 3.8 | -2.4 ± 4.0 | 0.7 ± 3.1 |
| p | n.a. | n.a. | n.a. | n.a. | 0.019 | 0.696 |
| Δ IGF 1 [ng/ml] | -52 ± 73 | 25 ± 40 | -19 ± 29 | 43 ± 55 | ||
| p | 0.002 | 0.116 | 0.197 | <0.001 | ||
| Δ IGF BP3 [μg/ml] | -0.1 ± 0.2 | 0.2 ± 0.2 | -0.1 ±0.3 | -0.1 ± 0.3 | 0.3 ± 0.2 | -0.1 ± 0.4 |
| p | 0.156 | <0.001 | 0.119 | 0.885 | <0.001 | 0.680 |
| Δ ACTH [pg/ml] | -7 ± 11 | 3 ± 6 | -11± 7 | 6 ± 12 | 1 ± 7 | 0 ± 7 |
| p | 0.001 | 0.210 | n.a. | n.a. | n.a. | n.a. |
| Δ TNF [pg/ml] | -0.1 ± 3.5 | -0.6 ± 3.2 | 0.6 ± 6.0 | -3.9 ± 6.2 | -0.5 ± 5.4 | 2.3 ± 7.3 |
| p | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| Δ ACTH/Cortisol [] *108 | -0.7 ± 0.5 | 0.3 ± 0.7 | 0.1 ± 0.4 | 0.2 ± 0.4 | ||
| p | n.a. | n.a. | n.a. | n.a. | ||
Means ± Standard deviations (for CRP: median (interquartile range)); Fatigue: day 8 minus day 1; Recovery: day 11 minus day 8; Bold letters: Fatigue dependent course for this parameter and exercise mode; n.a.: No post-hoc test was conducted due to lack of significant global effect for the repeat factor; CK: creatine kinase; f-T: free testosterone; Gln: glutamine; Glu: glutamate; IL-6: interleukin 6; HGH: human growth hormone; IGF-1: insulin like growth factor 1; IGF-BP3: IGF binding protein 3; ACTH: adreno-corticotropic hormone; TNF: tumor necrosis factor